Abstract 5077
Background
Women with OC due to an underlying BRCA mutation (BRCAm) are known to have enhanced responses to platinum and PLD, but their relative response rates to wpac are unclear. Both PLD and wpac are commonly used in women with PROC. Our aim was to assess the response rates to both agents, stratified by BRCAm staus.
Methods
Women with PR OC treated at The Royal Marsden Hospital between 2007 and 2017 with known BRCAm status were identified from the electronic patient record. Included patients underwent a minimum of 3 cycles and radiological restaging for inclusion. The primary endpoint was radiological response (RR) by BRCA status - BRCAm or BRCA wildtype (WT). Secondary endpoints were clinical benefit rate (CBR), CA-125 response, and line of treatment as a predictor of response.
Results
231 pt were identified, 38 BRCAm, 193 WT; median age 58 yrs (36-88) BRCAm, 62 yrs (44-85) WT. Histology was 90% HGS, 4% endometroid, 3% clear cell, 1% mucinous, 2% other. Overall 102 (44%) were treated with PLD; 129 (56%) received wpac with RR 14% PLD and 38% wpac; CBR of 49% PLD and 83% wpac (p = 0.01). When stratified by BRCAm, RR to PLD was 28% (BRCAm) vs 13% (WT; p = 0.01); and wpac 37% (BRCAm) vs 38% (WT, ns). CBR was 64% (BRCAm) vs 48% (WT) with PLD (p = 0.02) and 81% vs 83% with wpac (WT, ns). GCIG CA-125 responses were present in 110/231 (48%) – 24 PLD and 86 wpac, for CA-125 RR of 24% and 66% respectively (p < 0.001). Choice of first line treatment was PLD (49%) and wpac (51%); use in 2nd line was 44% and 56% respectively. Line of treatment was not an independent predictor of RR.
Conclusions
Within the limits of a retrospective audit, BRCAm carriers had significantly higher RR to PLD than WT patients; with equivalent responses to wpac. Wpac may be a preferred choice over PLD in BRCA WT patients with PROC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5629 - Outcome of triple negative inflammatory breast cancers (TNIBC) treated with dose dense neoadjuvant epirubicin cyclophosphmide, prognostic impact of pre and post neoadjuvant chemotherapy (NAC) tumor infiltrating lymphocytes (TIL) and post NAC lymphovascular invasion
Presenter: Luca Campedel
Session: Poster Display session 2
Resources:
Abstract
5792 - A novel PET parameter for cancer stem cell metabolism: early prediction of chemosensitivity to neoadjuvant chemotherapy in locally advanced breast cancer
Presenter: Chanwoo Kim
Session: Poster Display session 2
Resources:
Abstract
3728 - Using nodal ratio to predict recurrence in patients with 4 or more positive lymph nodes early stage breast cancer
Presenter: Besma Graja
Session: Poster Display session 2
Resources:
Abstract
3395 - Re-sentinel node biopsy for local recurrence after breast-conserving surgery
Presenter: Yuka Matsubara
Session: Poster Display session 2
Resources:
Abstract
4302 - Assessment of prognostic and therapeutic factors in men with breast cancer
Presenter: Daniel Herrero Rivera
Session: Poster Display session 2
Resources:
Abstract
4263 - Genomic Profiling of Chinese Breast Cancer Patients
Presenter: Zhonghua Tao
Session: Poster Display session 2
Resources:
Abstract
2406 - Genome copy number alteration burden represents predictor of response in long-term, never relapse exceptional responders of trastuzumab-treated HER2+ metastatic breast cancer
Presenter: Naomi Walsh
Session: Poster Display session 2
Resources:
Abstract
2575 - Next-generation DNA Sequencing (NGS) Results for Tumors From Phase 2 ABRAZO Study of Talazoparib After Platinum or Cytotoxic Non-Platinum Regimens in Patients (pts) With Advanced Breast Cancer (ABC) and Germline BRCA1/2 (gBRCA) Mutations
Presenter: Nicholas C. Turner
Session: Poster Display session 2
Resources:
Abstract
4499 - FGFR1 and CCND1 gene amplifications are associated with breast cancer resistance to aromatase inhibitors
Presenter: Evgeny Imyanitov
Session: Poster Display session 2
Resources:
Abstract
4110 - Clinicopathologic features of BRCA mutated breast cancer patients: Hacettepe Experience
Presenter: Sercan Aksoy
Session: Poster Display session 2
Resources:
Abstract